Standard
BUDGET IMPACT ANALYSIS OF THE TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH TYROSINE KINASE INHIBITORS - NILOTINIB IN THE FIRST AND SECOND LINES OF THERAPY. / Kolbin, A.; Frolov, M.; Kurylev, A.; Vilum, I; Balykina, Y.; Proskurin, M.
In:
Value in Health, Vol. 18, No. 7, 11.2015, p. A443-A443.
Research output: Contribution to journal › Meeting Abstract › peer-review
Harvard
Kolbin, A, Frolov, M, Kurylev, A, Vilum, I
, Balykina, Y & Proskurin, M 2015, '
BUDGET IMPACT ANALYSIS OF THE TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH TYROSINE KINASE INHIBITORS - NILOTINIB IN THE FIRST AND SECOND LINES OF THERAPY',
Value in Health, vol. 18, no. 7, pp. A443-A443.
APA
Kolbin, A., Frolov, M., Kurylev, A., Vilum, I.
, Balykina, Y., & Proskurin, M. (2015).
BUDGET IMPACT ANALYSIS OF THE TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH TYROSINE KINASE INHIBITORS - NILOTINIB IN THE FIRST AND SECOND LINES OF THERAPY.
Value in Health,
18(7), A443-A443.
Vancouver
Author
BibTeX
@article{531bb88d7877474b91d02959881ab45f,
title = "BUDGET IMPACT ANALYSIS OF THE TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH TYROSINE KINASE INHIBITORS - NILOTINIB IN THE FIRST AND SECOND LINES OF THERAPY",
author = "A. Kolbin and M. Frolov and A. Kurylev and I Vilum and Y. Balykina and M. Proskurin",
year = "2015",
month = nov,
language = "Английский",
volume = "18",
pages = "A443--A443",
journal = "Value in Health",
issn = "1098-3015",
publisher = "Elsevier",
number = "7",
}
RIS
TY - JOUR
T1 - BUDGET IMPACT ANALYSIS OF THE TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH TYROSINE KINASE INHIBITORS - NILOTINIB IN THE FIRST AND SECOND LINES OF THERAPY
AU - Kolbin, A.
AU - Frolov, M.
AU - Kurylev, A.
AU - Vilum, I
AU - Balykina, Y.
AU - Proskurin, M.
PY - 2015/11
Y1 - 2015/11
M3 - тезисы
VL - 18
SP - A443-A443
JO - Value in Health
JF - Value in Health
SN - 1098-3015
IS - 7
ER -
